Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When is the expected fda decision date for apotex's ruxolitinib resubmission?
The expiration date of the key patent for guselkumab?
How much is mebendazole?
Guselkumab loss of exclusitivy?
What's the recommended schedule for lurbinectedin side effect checks?

What is the impact of impaired liver function on tigecycline dosage?

See the DrugPatentWatch profile for tigecycline

Short answer:
For most patients with mild to moderate hepatic impairment, no dose adjustment of tigecycline is recommended. In severe hepatic dysfunction, the drug may accumulate and clinical judgment (often erring on the side of caution) is advised—some clinicians reduce the dose or shorten the treatment duration, but no formal dosing guideline exists.

Why the impact is usually small

Aspect Tigecycline pharmacology
Primary route of elimination 60 % biliary/fecal excretion, 2 % unchanged renal excretion.
Metabolism Minimal; the drug is largely excreted unchanged.
Dependence on liver function Low. Hepatic clearance is not a major determinant of total clearance.

Because the drug is not heavily metabolized or cleared by the liver, hepatic dysfunction tends to have a modest effect on its overall pharmacokinetics. Clinical pharmacokinetic studies have shown:

Hepatic impairment AUC change Clinical implication
Mild (Child‑Pugh A) ~+30 % Clinically insignificant.
Moderate (Child‑Pugh B) ~+40 % Still within therapeutic window.
Severe (Child‑Pugh C) Potentially > +50 % Possible accumulation; caution warranted.

The FDA/EMA prescribing information states:

“No dosage adjustment is necessary in patients with mild or moderate hepatic impairment.”
“Caution is advised in patients with severe hepatic impairment; dose adjustments are not formally recommended, and clinical judgment should guide therapy.”

Practical guidance for clinicians

Situation Recommendation
Mild–moderate hepatic dysfunction (e.g., ALT/AST 1–3× ULN, normal bilirubin) Standard dosing: 50 mg IV loading dose, then 30 mg IV q12 h. No adjustment needed.
Severe hepatic dysfunction (e.g., Child‑Pugh C, bilirubin > 2 mg/dL, prolonged prothrombin time) • Consider reducing the maintenance dose (e.g., 25 mg q12 h) or shortening duration.
• Monitor liver enzymes (ALT/AST) and bilirubin weekly.
• Be alert for signs of drug accumulation (e.g., prolonged QT, nausea).
Patients on other hepatically‑cleared antibiotics Tigecycline can be co‑administered safely; no dose changes required, but monitor for additive hepatotoxicity.
Pregnancy / lactation Hepatic impairment does not alter the recommendation; still contraindicated in pregnancy.

Monitoring

  • Baseline labs: AST, ALT, total bilirubin, INR.
  • Follow‑up: Repeat labs at week 1, then every 1–2 weeks.
  • Clinical signs: Jaundice, dark urine, right upper quadrant pain—consider alternate therapy if worsening.

Key points to remember

  1. No routine dose adjustment for mild–moderate hepatic impairment.
  2. Severe hepatic dysfunction: use clinical judgment, consider dose reduction or shorter courses, and monitor closely.
  3. Tigecycline can elevate liver enzymes—monitor even in patients with normal liver function.
  4. No contraindication in hepatic disease per se, but use cautiously in advanced liver disease.

Bottom line

Impaired liver function has a limited effect on tigecycline exposure; the drug’s standard dosing can be applied to patients with mild to moderate hepatic dysfunction without adjustment. In severe hepatic impairment, a cautious approach with close monitoring—and possibly a lower maintenance dose—helps prevent drug accumulation and potential toxicity. Always refer to the most recent product labeling and consider local institutional guidelines when making final dosing decisions.



Other Questions About Tigecycline :

the impact of efflux pumps on the tigecycline-induced resistance How much cheaper are tigecycline generics compared to brand name? How does tigecycline s cost affect antibiotic choice? How frequent are gi issues with tigecycline use? These questions aim to explore the impact of excipients on tigecycline's elimination process including absorption distribution metabolism and excretion understanding these interactions can help optimize tigecycline therapy and improve patient outcomes? Is there a specific duration of tigecycline treatment that increases gi issues? What role does mutation of bacterial ribosomal proteins play in tigecycline resistance?